title: CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS.
abstract: Employing antigens with expression restricted to normal intestinal mucosa and derivative colorectal tumors - cancer mucosa antigens (CMAs) - represents a novel paradigm in anti-tumor immunotherapy. Immune compartmentalization limits tolerance to CMAs and restricts mucosa-targeted autoimmunity, allowing safe and effective immunotherapy for metastatic colorectal cancer. Guanylyl cyclase C (GCC), an intestine/colorectal cancer-restricted protein, is poised for clinical evaluation as the index CMA.
authors: Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia PA 19107.
authors: Adam E
authors: AE
authors: Snook
authors: Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia PA 19107.
authors: Scott A
authors: SA
authors: Waldman